Receptor(SSTR2)-selective somatostatin antagonists
SRIF peptide antagonists, which are selective for SSTR2 in contrast to the other cloned SRIF receptors and which bind with high affinity to the cloned human receptor SSTR2 but do not activate the receptor, have many useful functions. Because they do not bind with significant affinity to SSTR1, SSTR3, SSTR4 or SSTR5, their administration avoids potential undesirable side effects. By incorporating radioiodine or the like in these SSTR2-selective SRIF antagonists, a labeled compound useful in drug-screening methods is provided. Alternatively, for use in therapy, highly radioactive moieties can be N-terminally coupled, complexed or chelated thereto. Because they block the receptor function, they can be used therapeutically to block certain physiological effects which SSTR2 mediates.
1. A cyclic somatostatin(SRIF) peptide antagonist which selectively binds the SRIF receptor SSTR2 without triggering internalization into a cell, which peptide comprises:
the amino acid sequence (cyclo3-14)Xaa 1 -Xaa 2 -D-Xaa 3 -Xaa 4 -Xaa 5 -Xaa 6 -Xaa 7 -Xaa 8 -Xaa 9 -Xaa 10 -Xaa 11 -Xaa 12 -Xaa 13 -Xaa 14 -Xaa 15
wherein:
Xaa 1 is des-Xaa;
Xaa 2 is pNO 2 -Phe or Cpa;
D-Xaa 3 is D-Cys, D-HCys or another D-isomer α-amino acid having an SH-side chain;
Xaa 4 , Xaa 5 and Xaa 6 are des-Xaa;
Xaa 7 is Aph(Hor), Aph(Cbm), Tyr or ITyr;
Xaa 8 is D-Trp or D-Aph(Cbm);
Xaa 9 is Lys;
Xaa 10 is Thr, Ser or Val;
Xaa 11 , Xaa 12 and Xaa 13 are des-Xaa;
Xaa 14 is Cys, hCys or another L-isomer α-amino acid having an SH side chain; and
Xaa 15 is 2Nal, D-2Nal, Tyr, or D-Tyr.
2. The peptide according to claim 1 , wherein Xaa 7 is Aph(Hor), Xaa 8 is D-Aph(Cbm) and Xaa 15 is 2Nal or D-Tyr.
3. The peptide according to claim 1 , wherein Xaa 2 is Cpa; Xaa 7 is Aph(Hor); and Xaa 8 is D-Aph(Cbm).
4. The peptide according to claim 1 , wherein Xaa 7 is Tyr.
5. The peptide according to claim 1 , wherein there is also present at the N-terminus a moiety Z which is a chelator, a complexing agent, a conjugating agent or a label.
6. The peptide according to claim 5 , wherein Z is selected from the group consisting of DOTA- and DTPA-based chelators, NOTA-based chelators, carbonyl compounds, 2-hydrazino nicotinamide, N 4 -chelators, desferrioxamin, and N x S y -chelators and wherein said moiety Z is optionally attached to Xaa 2 by a linker L.
7. A pharmaceutical composition comprising a mixture of the peptide according to claim 1 and at least one pharmaceutically acceptable carrier.
8. The peptide of claim 1 , which has one of the following amino acid sequences wherein the C-terminus is amidated:
9. The peptide of claim 1 , having one of the following amino acid sequences wherein the C-terminus is amidated:
10. The peptide of claim 1 , which has the following amino acid sequences, wherein the C-terminus is amidated:
11. The peptide of claim 1 , which has the following amino acid sequences, wherein the C-terminus is amidated:
12. The peptide of claim 1 , which has the following amino acid sequences, wherein the C-terminus is amidated:
13. The peptide of claim 1 , which has the following amino acid sequences, wherein the C-terminus is amidated:
14. The peptide of claim 1 , which has the following amino acid sequences, wherein the C-terminus is amidated:
15. The peptide of claim 1 , which has the following amino acid sequences, wherein the C-terminus is amidated:
16. The peptide of claim 1 , which has the following amino acid sequences, wherein the C-terminus is amidated:
17. The peptide of claim 1 , which has the following amino acid sequences, wherein the C-terminus is amidated: